Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)
Joint Authors
Edassery, Seby
Perambakam, Supriya
Peace, David J.
Xie, Hui
Source
Journal of Immunology Research
Issue
Vol. 2010, Issue 2010 (31 Dec. 2010), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2010-12-21
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses.
Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year.
Thirteen patients had stable or declining serum levels of PSA one year post-vaccination.
A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P=.02).
Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis.
A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.
American Psychological Association (APA)
Perambakam, Supriya& Xie, Hui& Edassery, Seby& Peace, David J.. 2010. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154). Journal of Immunology Research،Vol. 2010, no. 2010, pp.1-11.
https://search.emarefa.net/detail/BIM-989312
Modern Language Association (MLA)
Perambakam, Supriya…[et al.]. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154). Journal of Immunology Research No. 2010 (2010), pp.1-11.
https://search.emarefa.net/detail/BIM-989312
American Medical Association (AMA)
Perambakam, Supriya& Xie, Hui& Edassery, Seby& Peace, David J.. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154). Journal of Immunology Research. 2010. Vol. 2010, no. 2010, pp.1-11.
https://search.emarefa.net/detail/BIM-989312
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-989312